Phase-II Trial Of Bharat Biotech's Covaxin To Begin In September

Modesto Morganelli
Agosto 16, 2020

J&J said it has also agreed to collaborate with the United Kingdom government on a global Phase 3 trial to explore the two-dose regimen of its vaccine candidate.

The novel coronavirus, which has killed more than 750,000 people globally, has prompted a race to develop a vaccine. Meanwhile, there is news that the first phase of testing of the vaccine of Corona virus being made by Bhara Biotech has been completed. "However, they got better after a few hours of monitoring without any medical intervention", said a source at the Nagpur centre.

The European Commission has reached an agreement with pharmaceutical giant AstraZeneca PLC to purchase a potential vaccine against Covid-19 once it has been proven to be safe and effective. Before that, investigators are collecting blood samples from the voltiners, the examination of the blood sample will test the immunogenicity of the vaccine. Preparations are now underway to give Volunteers a second dose. "We have not observed any adverse events in any of the volunteers at our site".

Savita Verma said, 'Now we come to know that the vaccine is completely safe.

The Drugs Controller General of India granted permission to Bharat Biotech for Phase-I and II human clinical trials after it had submitted results generated from pre- clinical studies, demonstrating safety and immune response. For that, we have started taking blood samples.

Except for All India Institute of Medical Sciences (AIIMS), other centres have nearly completed their first phase of human trials. The government itself is watching all the developments.

Council of Medical Research (ICMR) and National Institute of Virology (NIV). Another investigator said on condition of anonymity that if all goes well, the vaccine will be available in the first half of next year.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE